1. MAPK/ERK Pathway
  2. p38 MAPK

Tat-NR2B9c 

Cat. No.: HY-P0117 Purity: 98.22%
Handling Instructions

Tat-NR2B9c is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1; Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy. Sequence: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Tat-NR2B9c Chemical Structure

Tat-NR2B9c Chemical Structure

CAS No. : 500992-11-0

Size Price Stock Quantity
1 mg USD 84 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 216 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 336 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
25 mg USD 660 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    Tat-NR2B9c purchased from MCE. Usage Cited in: J Cereb Blood Flow Metab. 2018 Jan 1:271678X18762637.

    Tat-NR2B9c affects PSD95-NR2B-nNOS complex and PSD95-neurexin-neuroligin complex formation after ICH. Western blots of IP with PSD95 antibody show the interactions between nNOS, NR2B, neurexin-1 or neuroligin-1, and PSD95.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Tat-NR2B9c is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1; Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy. Sequence: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val.

    IC50 & Target

    EC50: 6.7 nM (PSD-95d2), 670 nM (PSD-95d1)[1]
    p38[2]

    In Vitro

    Tat-NR2B9c is a PSD-95 inhibitor, with an EC50 of 6.7 nM for PSD-95d2, representing a >100-fold higher affinity for this domain than for PSD-95d1 (EC50, 0.67 μM). Tat-NR2B9c inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95, with IC50s of 0.5 μM, ∼8 μM, and 0.75 μM, respectively. Tat-NR2B9c also blocks the interaction between PSD-95 and nNOS with an IC50 of ∼0.2 μM[1]. Tat-NR2B9c reduces association of PSD-95 with GluN2B by ∼50% in the YAC128 striatum, decreases NMDA-induced p38 activation in YAC128 striatal tissue, but shows no effect on the NMDA-induced JNK activation[2].

    In Vivo

    Tat-NR2B9c (10 nM/g, i.v.) reduces infarction volume of male C57BL/6 mice, but has no effect at 3 nM/g[3].

    Solvent & Solubility
    In Vitro: 

    10 mM in H2O

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.3970 mL 1.9850 mL 3.9700 mL
    5 mM 0.0794 mL 0.3970 mL 0.7940 mL
    10 mM 0.0397 mL 0.1985 mL 0.3970 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Tat-NR2B9c is prepared in saline[4].

    References
    Cell Assay
    [2]

    Postnatal mono-cultured WT and YAC128 striatal neurons (DIV 9, due to the viability of these mono-cultured MSNs) are pretreated for 1 h with 200 nM Tat-NR2B9c, and/or SB-239063 (p38 inhibitor), and/or SP-600125 (JNK inhibitor), then incubated with or without 500 μM NMDA for 10 min. After NMDA treatment, striatal neurons are washed once with warm plating medium (PM) and then incubated in conditioned PM (without Tat peptides or p38, JNK inhibitors) for 24 h. Then cells are washed with PBS once and fixed with 4% paraformaldehyde (PFA) for 30 min[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    Mice[3]
    In each study mice are randomly allocated to three treatment groups (0.0, 3.0, 10.0 nMole/g Tat-NR2B9c) or to sham treatment. The individual performing the experimental procedures, administering treatments and performing the analyses is blinded to the treatment assignments. Tat-NR2B9c is prepared at the indicated doses and administered intravenously via the tail vein using a pump in a volume of 1 µL/g over 5 min beginning at reperfusion[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    2518.88

    Formula

    C₁₀₅H₁₈₈N₄₂O₃₀

    CAS No.

    500992-11-0

    Storage
    Powder -80°C 2 years
      -20°C 1 year
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tat-NR2B9c
    Cat. No.:
    HY-P0117
    Quantity:

    Tat-NR2B9c

    Cat. No.: HY-P0117